Targeting of tumor endothelial cells combining 2 Gy/day of X-ray with Everolimus is the effective modality for overcoming clinically relevant radioresistant tumors.
Bottom Line: Radiotherapy is widely used to treat cancer because it has the advantage of physically and functionally conserving the affected organ.Everolimus with FR markedly reduced SAS and SAS-R tumor volumes.We conclude that FR combined with Everolimus may be an effective modality to overcome radioresistant tumors via targeting tumor ECs.
Affiliation: Department of Pathology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, 980-8575, Japan.Show MeSH
Related in: MedlinePlus
Mentions: Connective tissues were more abundant in SAS-R tumors than in SAS tumors (Fig. 1B). This observation prompted us to examine MVD in SAS and SAS-R tumors. CD34 immunostaining confirmed that MVD in SAS-R tumors was higher than in SAS tumors (Fig. 2A). Tomato lectin labeling of the luminal EC surface showed that MVD with blood flow was higher in SAS-R tumors compared to in SAS tumors (Fig. 2B). This suggested that angiogenesis was activated in SAS-R tumors. MVD was also higher in HeLa-R tumors than in HeLa tumors (data not shown).
Affiliation: Department of Pathology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, 980-8575, Japan.